Minerva Neurosciences traded at $3.25 this Tuesday July 5th, decreasing $0.34 or 9.47 percent since the previous trading session. Looking back, over the last four weeks, Minerva Neurosciences lost 760.24 percent. Over the last 12 months, its price rose by 40.09 percent. Looking ahead, we forecast Minerva Neurosciences to be priced at 3.49 by the end of this quarter and at 3.22 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 3,862.00 24.00 0.63% 4.80%
Acadia Pharmaceuticals 15.27 0.90 6.26% -36.72%
Adma Biologics 2.13 0.10 4.93% 41.06%
ALKERMES 31.43 0.90 2.95% 22.97%
AstraZeneca 10,943.24 143.24 1.33% 26.39%
BioCryst Pharmaceuticals 11.14 0.30 2.77% -31.36%
Bristol-Myers Squibb 75.96 -0.88 -1.15% 13.97%
Dynavax Technologies 14.02 1.06 8.18% 47.58%
Esperion Therapeutics 6.99 0.54 8.37% -64.80%
GlaxoSmithKline 1,794.20 7.60 0.43% 24.86%
Halozyme Therapeutics 46.33 1.85 4.16% 0.30%
Ionis Pharmaceuticals 37.85 -0.21 -0.55% -3.76%
J&J 178.14 -1.38 -0.77% 6.05%
Eli Lilly 327.18 2.47 0.76% 38.98%
Merck & Co 92.64 0.22 0.24% 18.60%
Marinus Pharmaceuticals 5.02 0.26 5.46% -73.21%
Neurocrine Biosciences 98.30 -0.95 -0.96% 0.87%
Minerva Neurosciences 3.25 -0.34 -9.47% 40.09%
Novartis 81.30 0.39 0.48% -4.32%
Novavax 64.29 7.14 12.49% -70.12%
Pfizer 51.64 -0.67 -1.28% 31.43%
Roche Holding 322.90 3.90 1.22% -9.29%
Sanofi 97.90 0.78 0.80% 12.79%
Vanda Pharmaceuticals 11.50 0.31 2.77% -43.41%

Indexes Price Day Year
USND 11322 194.39 1.75% -22.79%

Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on development and commercialization of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company's lead product candidates are roluperidone (MIN-101), MIN-301, and seltorexant. Roluperidone (MIN-101) is a compound that blocks serotonin, sigma, and a adrenergic receptors that are involved in the regulation of mood, cognition, sleep, and anxiety. The Company is developing roluperidone to treat patients with schizophrenia. Roluperidone is designed to block a specific subtype of serotonin receptor called 5-HT2A. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 (NRG-1b1), protein, for the treatment of Parkinson’s disease and for other neurodegenerative disorders. The Company is developing seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD).